Olverembatinib

1257628-77-5

Bcr-Abl

Cytoskeletal Signaling, Tyrosine Kinase/Adaptors, Angiogenesis

>99.99%

Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl (WT, IC50: 0.34 nM) and Bcr-Abl (T315I, IC50: 0.68 nM) .

CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1

C29H27F3N6O

532.56

Ice Packs

-20°C